Tumor therapy by radiolabelled metal ligand complexes - a new concept
Creators
- 1. Zentralinstitut fuer Kernforschung, Rossendorf bei Dresden (German Democratic Republic). Abt. Radioisotope
- 2. Zentralinstitut fuer Kernforschung, Rossendorf bei Dresden (German Democratic Republic). Abt. Strahlenschutz
- 3. Medizinische Akademie, Dresden (German Democratic Republic). Nuklearmedizinische Klinik
Description
A new conception of tumor therapy by means of radionuclides is presented. Former own studies with various radioactive metal ligand complexes showed an high skeletal besides the intratumoral uptake of radioactivity. This is, however, infavourable regarding the application of these metal ligand complexes for tumor therapy. The aim of this study was to increase the tumor uptake via the preapplication of tracer amounts of stable yttrium. In fact, 169Yb applied as hydroxi-ethyle-ethylene-diamino-tri-acetate (HEDTA) showed a considerably lower accumulation of radioactivity in bone tissue after the preapplication of stable substance than without additional supply. For therapeutic use in tumor treatment, 169Yb could be substituted by the alpha-emitter 225Ac because of the high therapeutic efficiency of the latter. Assuming this substitution, the tumor/background radiation dose ratio could be enhanced after preapplication of stable yttrium up to the 90-fold. (orig.)
Abstract (German)
Ein neues Tumortherapie-Konzept mit Radionukliden wird vorgestellt. Fruehere eigene Studien mit verschiedenen radioaktiven Metalliganden-Komplexen zeigten neben dem intratumoralen einen hohen Skelett-Uptake. Dies ist jedoch hinsichtlich der Applikation der Metalliganden-Komplexe fuer eine Tumortherapie unguenstig. Das Ziel dieser Studie bestand in der Erhoehung des Tumor-Uptakes mittels vorheriger Applikation von stabilem Yttrium. Tatsaechlich ergab 169Yb in Form von Hydroxy-aethyl-aethylen-diamin-triacetat (HEDTA) nach Vorapplikation der stabilen Substanz eine wesentlich geringere Radioaktivitaets-Speicherung im Knochengewebe als ohne diese zusaeztliche Gabe. 169Yb koennte fuer die Tumortherapie durch den Alpha-Strahler 225Ac wegen dessen hoeherer therapeutischer Effizienz ersetzt werden. Diese Substitution wuerde den Energiedosis-Quotienten Tumor/Background nach Vorapplikation von stabilem Yttrium bis zu 90fach erhoehen. (orig.)Additional details
Publishing Information
- Journal Title
- Nuc Compact
- Journal Volume
- 19
- Journal Issue
- 3
- Series
- Nuc Compact.
- Journal Page Range
- 100-102
- ISSN
- 0344-3752
- CODEN
- CNNMA
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 20005685
- Subject category
- S63: RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS; S61: RADIATION PROTECTION AND DOSIMETRY;
- Descriptors DEI
- ACTINIUM 225; COMPARATIVE EVALUATIONS; EFFICIENCY; HEDTA; LIGANDS; MICE; NEOPLASMS; RADIATION DOSES; RADIONUCLIDE KINETICS; SKELETON; THERAPY; TISSUE DISTRIBUTION; UPTAKE; YTTERBIUM 169; YTTRIUM
- Descriptors DEC
- ACTINIDE NUCLEI; ACTINIUM ISOTOPES; ALPHA DECAY RADIOISOTOPES; AMINO ACIDS; ANIMALS; BETA DECAY RADIOISOTOPES; BODY; CARBOXYLIC ACIDS; CHELATING AGENTS; DAYS LIVING RADIOISOTOPES; DISEASES; DISTRIBUTION; ELECTRON CAPTURE RADIOISOTOPES; ELEMENTS; EVALUATION; EVEN-ODD NUCLEI; HEAVY NUCLEI; HYDROXY ACIDS; INTERMEDIATE MASS NUCLEI; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; KINETICS; MAMMALS; MEDICINE; METALS; NUCLEI; ODD-EVEN NUCLEI; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANS; RADIOISOTOPES; RARE EARTH NUCLEI; RODENTS; SECONDS LIVING RADIOISOTOPES; TRANSITION ELEMENTS; VERTEBRATES; YTTERBIUM ISOTOPES